Wenjian Gong
1095 Jiefang Ave
Wuhan, China
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 25, 2026
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy.
Journal: Journal of hematology & oncology
Published: March 04, 2026
Deep learning prediction model based on multi-modal transvaginal ultrasound scan images for endometrial cancer.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: November 11, 2025
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: October 20, 2025
Phosphorylated IRF3 promotes GSDME-mediated pyroptosis through RIPK1/FADD/caspase-8 complex formation during mitotic arrest in ovarian cancer.
Journal: Cell communication and signaling : CCS
Published: March 20, 2025
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.
Journal: Biomarker research
Published: March 13, 2025
Dynamic changes in peripheral blood immunophenotyping and its prognostic value in cervical cancer patients undergoing immune checkpoint blockade therapy.
Journal: Discover oncology
Published: September 27, 2024
New insights into the stemness of adoptively transferred T cells by γc family cytokines.
Journal: Cell communication and signaling : CCS
Published: August 30, 2023
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.
Journal: Cell
Published: January 18, 2023
Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis.
Journal: Journal of ovarian research
Published: October 26, 2021
Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma.
Journal: Aging
Published: June 11, 2021
Last Updated: 09/26/2026